Understanding cognitive decline and mild cognitive impairment in Alzheimer's disease
Official title: AlfaCognition: Longitudinal Study for the Characterization of the Phases of Subjective Perception of Cognitive Decline and Mild Cognitive Impairment of Alzheimer's Disease.
Run by Barcelonabeta Brain Research Center, Pasqual Maragall Foundation · NCT03851523 · Data updated 2026-11-12
This study looks at how people with different levels of memory issues, including those with Alzheimer's, feel about their cognitive decline to better understand how it progresses.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 45 Years and up |
| Sex | All |
| Enrollment | 400 (estimated) |
| Sponsor | Barcelonabeta Brain Research Center, Pasqual Maragall Foundation Academic / other |
| Locations | 1 site (Barcelona, Catalonia) |
| Status | Recruiting |
| Started | February 12, 2018 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2027 |
| Registry record updated | May 31, 2025 |
| Trial ID | NCT03851523 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include men and women aged 45 to 74 with subjective cognitive decline, mild cognitive impairment, or mild dementia.
✕Probably not a fit
Patients with significant systemic illnesses or cognitive impairments unrelated to Alzheimer's disease may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to characterize the phases of subjective perception of cognitive decline and mild cognitive impairment associated with Alzheimer's disease. It involves assessing cognitively healthy individuals, those with subjective cognitive decline, mild cognitive impairment, and mild dementia. Participants will be evaluated through subjective memory complaints and clinical interviews, with the involvement of a relative to provide additional insights. The study seeks to enhance understanding of the progression of cognitive decline in Alzheimer's disease without any direct interventions.
Why it matters
Potential benefit: If successful, this study could improve early detection and understanding of cognitive decline in Alzheimer's disease, leading to better patient management.
How similar studies have gone: Other studies have shown success in understanding cognitive decline in Alzheimer's disease, making this approach relevant and potentially impactful.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Men and women between 45 and 74 years at the time of inclusion in the 45-65/FPM2012 study or older than 45 for persons who have not previously participated in 45-65/FPM2012. 2. Cognitively healthy persons with SCD, as well as people with MCI and mild dementia. 3. Participation of a relative to perform the subjective memory complaint and clinical interview. Exclusion criteria: 1. Any significant systemic illness or unstable medical condition which could lead to difficulty complying with the protocol. 2. Any significant disorder that could course with cognitive impairment that is not related to AD. 3. Family history of monogenic AD.
Where it's running
-
Barcelonabeta Brain Research Center
Barcelona, Catalonia, Spain Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Blood tests using plasma biomarkers to diagnose and track Alzheimer’s disease
A large, year-long study in Milan is testing whether blood markers can help diagnose Alzheimer’s and predict how it will progress in people with memory concerns.
-
Effects of social isolation and interaction on dementia risk in people with subjective cognitive decline
This study is trying to see how being socially isolated or interacting with others affects the risk of dementia in people who notice early signs of memory problems.
-
Gut methane and Parkinson's: measuring if a probiotic helps people with Parkinson's, REM sleep behavior disorder, or cognitive concerns
This study tests whether a probiotic containing Limosilactobacillus reuteri can help people with Parkinson's disease, those at high risk for PD, and related cognitive issues by potentially improving gut methane levels and overall symptoms.
-
Music for Pain and Dementia: Group Drumming for people with early dementia and their caregivers
This study tests whether group drumming can reduce pain and change brain activity in people with mild dementia or mild cognitive impairment and in their caregivers.
-
Predicting cognitive test scores from narrated stories using AI
We will test whether an AI program can estimate standard cognitive test scores from short recorded storytelling tasks in people aged 50 and older with memory or thinking concerns.
-
Fast-track screening to determine eligibility for anti-amyloid treatment using digital cognitive tests and blood biomarkers.
This project will test whether combining self‑administered digital cognitive tests with blood biomarker results can quickly identify patients referred for memory concerns who may qualify for anti‑amyloid disease‑modifying therapy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.